Urological decline
April 17, 2012
A NEW GBI Research report is
predicting that major
pharmaceutical companies will lose
their hold on the urological
disorders market by 2017.
This trend, according to the
report is based entirely on multiple
patent expiries which began in
2009 and will continue through
until 2017.
Patent expiries of leading drugs
are expected to erode the 72%
market share held in 2010 by
Johnson & Johnson, Boehringer
Ingelheim, Astellas Pharma, Pfizer,
and GlaxoSmithKline, with Astellas
Flomax (tamsulosin) and J&J’s
Levaquin (levofloxacin) already
having lost their patents in 2009
and 2010 respectively.
Drugs set to lose patent
protection in the coming years
include, Pfizer’s Detrol (tolterodine)
in September 2012, J&J’s Doribax in
2015 and GSK’s Avodart in 2015.
The global urological market was
estimated to be worth $8.1b in
2010, and is forecast to increase
in the future to exceed $10b by 2017.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 Apr 12To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Apr 12
